U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H15N3O2S
Molecular Weight 265.3329
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALBENDAZOLE

SMILES

CCCSc1ccc2c(c1)[nH]c(n2)N=C(O)OC

InChI

InChIKey=HXHWSAZORRCQMX-UHFFFAOYSA-N
InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)

HIDE SMILES / InChI

Molecular Formula C12H15N3O2S
Molecular Weight 265.3329
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11386684

ALBENZA (albendazole) is an orally administered anthelmintic drug. Chemically, it is methyl 5¬ (propylthio)-2-benzimidazolecarbamate, is indicated to treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. In addition, treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. Albendazole binds to the colchicine-sensitive site of β-tubulin inhibiting their polymerization into microtubules. The decrease in microtubules in the intestinal cells of the parasites decreases their absorptive function, especially the uptake of glucose by the adult and larval forms of the parasites, and depletes glycogen storage. Insufficient glucose results in insufficient energy for the production of adenosine trisphosphate (ATP) and the parasite eventually dies. Albendazole developed in 1975. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just >1% . Albendazole's unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92%, for A. duodenale in 23 studies and 75% for N. americanus in 30 studies), A. lumbricoides (95% in 64 studies), T. trichiura (48% in 57 studies), E. vermicularis (98% in 27 studies), S. stercoralis (62% in 19 studies), H. nana (68% in 11 studies), and Taenia spp. (85% in 7 studies).

CNS Activity

Curator's Comment:: Albendazole penetrates blood–brain barrier, with concentrations in CSF reaching 50% of that found in plasma

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ALBENZA

Approved Use

ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. (1.1) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. (1.2) 1.1 Neurocysticercosis ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. 1.2 Hydatid Disease ALBENZA is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

Launch Date

8.3445121E11
Curative
ALBENZA

Approved Use

ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. (1.1) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. (1.2) 1.1 Neurocysticercosis ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. 1.2 Hydatid Disease ALBENZA is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

Launch Date

8.3445121E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
39.61 ng/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE SULFONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1310 ng/mL
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALBENDAZOLE OXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
707.37 ng/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE OXIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
284.55 ng × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE SULFONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3713.96 ng × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE OXIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.91 h
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE SULFONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8 h
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALBENDAZOLE OXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
11.43 h
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE OXIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALBENDAZOLE OXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Doses

Doses

DosePopulationAdverse events​
1200 mg 2 times / day multiple, oral
MTD
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources: Page: p.600
unhealthy, 25–81
n = 9
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 25–81
Sex: M+F
Population Size: 9
Sources: Page: p.600
Disc. AE: Neutropenic sepsis...
AEs leading to
discontinuation/dose reduction:
Neutropenic sepsis (grade 5, 11%)
Sources: Page: p.600
3200 mg 1 times / day multiple, oral
Highest studied dose
unhealthy, 38
n = 1
Disc. AE: Parkinsonism aggravated...
16 g single, oral (total daily dose)
Overdose
Dose: 16 g
Route: oral
Route: single
Dose: 16 g
Sources: Page: p.10
unhealthy
n = 1
Health Status: unhealthy
Condition: Hydatid Disease
Population Size: 1
Sources: Page: p.10
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources: Page: p.6
Disc. AE: Granulocytopenia, Pancytopenia...
Other AEs: Bone marrow depression, Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Granulocytopenia (grade 5)
Pancytopenia (grade 5)
Other AEs:
Bone marrow depression
Aplastic anemia
Agranulocytosis
Disorder fetal
Sources: Page: p.6
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease
Sources: Page: p.9
Disc. AE: Hepatic dysfunction NOS...
AEs leading to
discontinuation/dose reduction:
Hepatic dysfunction NOS (3.8%)
Sources: Page: p.9
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources: Page: p.9
Disc. AE: Leukopenia...
AEs leading to
discontinuation/dose reduction:
Leukopenia (0.7%)
Sources: Page: p.9
AEs

AEs

AESignificanceDosePopulation
Neutropenic sepsis grade 5, 11%
Disc. AE
1200 mg 2 times / day multiple, oral
MTD
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources: Page: p.600
unhealthy, 25–81
n = 9
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 25–81
Sex: M+F
Population Size: 9
Sources: Page: p.600
Parkinsonism aggravated Disc. AE
3200 mg 1 times / day multiple, oral
Highest studied dose
unhealthy, 38
n = 1
Agranulocytosis
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources: Page: p.6
Aplastic anemia
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources: Page: p.6
Bone marrow depression
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources: Page: p.6
Disorder fetal
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources: Page: p.6
Granulocytopenia grade 5
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources: Page: p.6
Pancytopenia grade 5
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources: Page: p.6
Hepatic dysfunction NOS 3.8%
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease
Sources: Page: p.9
Leukopenia 0.7%
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Hydatid Disease|Neurocysticercosis
Sources: Page: p.9
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
inconclusive
inconclusive
inconclusive
inconclusive
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Optimising the benefits of anthelmintic treatment in children.
2001
Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia.
2001
Comparison of worm control strategies in grazing sheep in Denmark.
2001
Albendazole therapy in the treatment of hydatid liver disease.
2001
Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle.
2001 Apr
Echinococcosis of the spleen during pregnancy.
2001 Apr
Susceptibility of avian hosts to experimental Gymnophalloides seoi infection.
2001 Apr
A comparative study of different albendazole and mebendazole regimens for the treatment of intestinal infections in school children of Usigu Division, western Kenya.
2001 Apr
[Disseminated strongyloidiasis].
2001 Apr 28
Microsporidiosis in the graft of a renal transplant recipient.
2001 Aug
Ocular and orbital cysticercosis.
2001 Aug
Ivermectin treatment of a traveler who returned from Peru with cutaneous gnathostomiasis.
2001 Aug 15
[Strongyloides stercoralis infestation in patients with chronic obstructive lung disease in Vega del Segura (Murcia). 3 case reports].
2001 Feb
Chemotherapy of enterobiasis (oxyuriasis).
2001 Feb
Pharmacotherapy of ascariasis.
2001 Feb
Cutaneous larva migrans contracted in England: a reminder.
2001 Jul
Proposed diagnostic criteria for neurocysticercosis.
2001 Jul 24
Gnathostomiasis.
2001 Jul 28
Strongyloides stercoralis eggs in the stools during anticancer therapy.
2001 Jul-Aug
Retroperitoneal localization of hydatid cyst disease.
2001 Jul-Aug
Parasitic cysts of the liver - practical approach to diagnosis and differentiation.
2001 Jul-Aug
Epidemiology of swine trichinellosis in China.
2001 Jun
Efficacy of flubendazole and albendazole against Trichinella spiralis in mice.
2001 Jun
Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes.
2001 Jun
Cerebral cysticercus granuloma associated with a subdural effusion.
2001 Jun
Pharmacokinetics of ricobendazole in calves.
2001 Jun
Treatment of ocular toxocariasis with albendazole.
2001 Jun
[Echinococcosis of the pelvic bone: four cases].
2001 Jun
[Vertebral hydatidosis: three case reports].
2001 Jun
Intestinal helminth infections, anaemia and labour productivity of female tea pluckers in Bangladesh.
2001 Jun
Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions: prognostic factors on long-term follow-up.
2001 Jun
The management of liver hydatid cysts by percutaneous drainage.
2001 Jun
Late onset temporal lobe epilepsy with MRI evidence of mesial temporal sclerosis following acute neurocysticercosis: case report.
2001 Jun
An unusual cause of renal colic: hydatiduria.
2001 Jun
Medullary gnathostomiasis in a white patient: use of immunodiagnosis and magnetic resonance imaging.
2001 Jun 1
Control of anthelmintic resistant endoparasites in a commercial sheep flock through parasite community replacement.
2001 Jun 12
Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract.
2001 Jun 19
Anthelmintic resistance on goat farms in Georgia: efficacy of anthelmintics against gastrointestinal nematodes in two selected goat herds.
2001 Jun 28
Synthesis and hydrolytic stability studies of albendazole carrier prodrugs.
2001 Jun 4
Activity of oxyclozanide, nitroxynil, clorsulon and albendazole against adult triclabendazole-resistant Fasciola hepatica.
2001 Jun 9
Albendazole therapy and reduced decline in haemoglobin concentration during pregnancy (Sierra Leone).
2001 Mar-Apr
Cystic echinococcosis in semi-nomadic pastoral communities in north-west China.
2001 Mar-Apr
In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes.
2001 Mar-Apr
[Human microsporidiosis].
2001 May
Some aspects in the control of schistosomosis and soil-transmitted helminthosis in Yemeni children.
2001 May
Effect of ruminal microflora on the biotransformation of netobimin, albendazole, albendazole sulfoxide, and albendazole sulfoxide enantiomers in an artificial rumen.
2001 May
Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis.
2001 May-Jun
[Orthopedic aspects of osseous echinococcosis--radiologic diagnosis, current surgery and drug therapy aspects].
2001 May-Jun
Integrated programme for control of geohelminths: a perspective.
2001 May-Jun
[Neurocysticercosis].
2001 May-Jun
Patents

Patents

Sample Use Guides

Patients weighing 60 kg or greater, 400 mg twice daily; less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily dose 800 mg). Hydatid disease: 28-day cycle followed by 14-day albendazole-free interval for a total of 3 cycles. Neurocysticercosis: 8 to 30 days.
Route of Administration: Oral
The antiproliferative effect of Albendazole (ABZ) on parent PTX-sensitive 1A9 and PTX-resistant sub-line 1A9PTX22 cells (human ovarian cancer)were compared to those induced by colchicine and paclitaxel (PTX). Cells were exposed to drugs for 3 days (colchicine) or 5 days (ABZ and PTX). The results demonstrate the inhibitory effect on 1A9 and 1A9PTX22 cells by ABZ (IC50=237 nM ± 3.65 and 351 nM ± 90 respectively).
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:54:30 UTC 2021
Edited
by admin
on Fri Jun 25 20:54:30 UTC 2021
Record UNII
F4216019LN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALBENDAZOLE
EP   GREEN BOOK   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
ALBENDAZOLE [INN]
Common Name English
ALBENDAZOLE [USP-RS]
Common Name English
ALBENDAZOLE [USAN]
Common Name English
ALBENZA
Brand Name English
SK&F 62979
Code English
METHYL 5-(PROPYLTHIO)BENZIMIDAZOL-2-YLCARBAMATE
Systematic Name English
ALBENDAZOLE [MI]
Common Name English
ALBENDAZOLE [WHO-DD]
Common Name English
ZENTEL
Brand Name English
METHYL N-(5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
Systematic Name English
ALBENDAZOLE [WHO-IP]
Common Name English
ALBENDAZOLE [EP MONOGRAPH]
Common Name English
ALBENDAZOLE [USP MONOGRAPH]
Common Name English
ALBENDAZOLE [VANDF]
Common Name English
SK&F-62979
Code English
METHYL 5-(PROPYLTHIO)-2-BENZIMIDAZOLECARBAMATE
Common Name English
ALBENDAZOLE [JAN]
Common Name English
CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER
Common Name English
ALBENDAZOLE [HSDB]
Common Name English
ALBENDAZOLE [GREEN BOOK]
Common Name English
ESKAZOLE
Brand Name English
ALBENDAZOLE [MART.]
Common Name English
ALBENDAZOLE [ORANGE BOOK]
Common Name English
ALBENDAZOLUM [WHO-IP]
Common Name English
ANDAZOL
Brand Name English
NSC-220008
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 94295
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.1.1
Created by admin on Fri Jun 25 20:54:31 UTC 2021 , Edited by admin on Fri Jun 25 20:54:31 UTC 2021
CFR 21 CFR 520.38A
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
WHO-ATC P02CA03
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
CFR 21 CFR 520.38
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
NCI_THESAURUS C250
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
WHO-VATC QP52AC11
Created by admin on Fri Jun 25 20:54:31 UTC 2021 , Edited by admin on Fri Jun 25 20:54:31 UTC 2021
CFR 21 CFR 520.38B
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
CFR 21 CFR 556.34
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
FDA ORPHAN DRUG 94195
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
LIVERTOX 17
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
NDF-RT N0000175481
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.1.2
Created by admin on Fri Jun 25 20:54:31 UTC 2021 , Edited by admin on Fri Jun 25 20:54:31 UTC 2021
Code System Code Type Description
FDA UNII
F4216019LN
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
MERCK INDEX
M1473
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY Merck Index
HSDB
7444
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
PUBCHEM
2082
Created by admin on Fri Jun 25 20:54:31 UTC 2021 , Edited by admin on Fri Jun 25 20:54:31 UTC 2021
PRIMARY
RXCUI
430
Created by admin on Fri Jun 25 20:54:31 UTC 2021 , Edited by admin on Fri Jun 25 20:54:31 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB00518
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
CAS
54965-21-8
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
WIKIPEDIA
ALBENDAZOLE
Created by admin on Fri Jun 25 20:54:31 UTC 2021 , Edited by admin on Fri Jun 25 20:54:31 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ALBENDAZOLE
Created by admin on Fri Jun 25 20:54:31 UTC 2021 , Edited by admin on Fri Jun 25 20:54:31 UTC 2021
PRIMARY Description: A white or almost white powder. Solubility: Practically insoluble in water; soluble in glacial acetic acid R; slightly soluble in acetone R, very slightly soluble in ethanol (~750 g/l) TS. Category: Anthelminthic. Storage: Albendazole should be kept in a well-closed container, protected from light. Additional information: Melting temperature, about 210?C, with decomposition. Requirement: Albendazole contains not less than 98.0% and not more than 101.0% of C12H15N3O2S, calculated with reference to the dried substance.
MESH
D015766
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
NDF-RT
N0000191624
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY Cytochrome P450 1A Inducers [MoA]
USP_CATALOG
1012553
Created by admin on Fri Jun 25 20:54:31 UTC 2021 , Edited by admin on Fri Jun 25 20:54:31 UTC 2021
PRIMARY USP-RS
NCI_THESAURUS
C47384
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
INN
3967
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
EVMPD
SUB05295MIG
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
ChEMBL
CHEMBL1483
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
DRUG CENTRAL
103
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
EPA CompTox
54965-21-8
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
LACTMED
Albendazole
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
ECHA (EC/EINECS)
259-414-7
Created by admin on Fri Jun 25 20:54:30 UTC 2021 , Edited by admin on Fri Jun 25 20:54:30 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities B and C: maximum 0.4 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities B and C: maximum 0.4 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC